Sci Signal:乳腺癌细胞代谢异常研究新突破

2017-12-26 陈扬 “医海拾贝微转化”微信号

甲硫氨酸(Met)依赖性是肿瘤细胞代谢异常的重要特征之一。所谓肿瘤Met依赖性是指与相应正常组织细胞不同,肿瘤细胞在去除Met(又称Met限制)的环境中 (即用Met的前体物质同型半胱氨酸取代Met)无法生长 。近日来自哈佛大学的一项研究发表在《Science Signaling》,揭示了因PI3KCA基因突变而驱动的乳腺癌,可抑制胱氨酸转运通道,而导致癌细胞对Met的依赖。

甲硫氨酸(Met)依赖性是肿瘤细胞代谢异常的重要特征之一。所谓肿瘤Met依赖性是指与相应正常组织细胞不同,肿瘤细胞在去除Met(又称Met限制)的环境中 (即用Met的前体物质同型半胱氨酸取代Met)无法生长 。近日来自哈佛大学的一项研究发表在《Science Signaling》,揭示了因PI3KCA基因突变而驱动的乳腺癌,可抑制胱氨酸转运通道,而导致癌细胞对Met的依赖。

研究者从13种乳腺癌细胞系中筛选出对Met去除不耐受的细胞系,发现这些细胞系大都携带PIK3CA基因的突变,因此推测致癌基因PIK3CA可能参与Met代谢过程。后续研究发现PIK3CA基因的突变导致SLC7A11的表达降低。SLC7A11编码胱氨酸转运蛋白xCT。xCT是哺乳动物重要的抗氧化蛋白,参与胱氨酸转运通道。细胞通过xCT吸收胱氨酸合成生物抗氧化剂——谷胱甘肽,用于清除多余的氧化自由基。生理状态下,xCT的作用是促进细胞内谷胱甘肽的产生,消除氧化自由基对于细胞损害,起着保护细胞生存的作用。进一步机制研究发现:致癌基因PIK3CA的异常活跃不仅降低xCT的表达, 还通过AKT-介导的磷酸化抑制了xCT蛋白质的活性。由于xCT蛋白对氨基酸生产的原料供应起作用,因此导致细胞Met生产受到限制。

这项研究为乳腺癌提供了全新的治疗视角。这种治疗方法的优势在于考虑到了正常组织细胞和肿瘤细胞在Met依赖方面的不同,在治疗肿瘤细胞的同时,不影响正常细胞代谢,使得Met限制性治疗方法 (Met 抑制剂)用于乳腺癌病人更具合理性。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2036164, encodeId=d25720361647f, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Fri May 25 09:03:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793987, encodeId=5aa11e9398759, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Jun 13 20:03:00 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724967, encodeId=0b381e2496788, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Fri Jul 20 22:03:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273402, encodeId=fe622e3402c4, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Dec 29 06:36:22 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252432, encodeId=67491252432c8, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Dec 28 10:03:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529464, encodeId=1a6715294645b, content=<a href='/topic/show?id=ba3be7774b6' target=_blank style='color:#2F92EE;'>#细胞代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77774, encryptionId=ba3be7774b6, topicName=细胞代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=771d11946860, createdName=yangshch, createdTime=Thu Dec 28 10:03:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631788, encodeId=ef441631e88ee, content=<a href='/topic/show?id=875e2542699' target=_blank style='color:#2F92EE;'>#代谢异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25426, encryptionId=875e2542699, topicName=代谢异常)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c06e21824720, createdName=bettycmoon, createdTime=Thu Dec 28 10:03:00 CST 2017, time=2017-12-28, status=1, ipAttribution=)]
    2018-05-25 楚秀娟
  2. [GetPortalCommentsPageByObjectIdResponse(id=2036164, encodeId=d25720361647f, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Fri May 25 09:03:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793987, encodeId=5aa11e9398759, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Jun 13 20:03:00 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724967, encodeId=0b381e2496788, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Fri Jul 20 22:03:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273402, encodeId=fe622e3402c4, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Dec 29 06:36:22 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252432, encodeId=67491252432c8, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Dec 28 10:03:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529464, encodeId=1a6715294645b, content=<a href='/topic/show?id=ba3be7774b6' target=_blank style='color:#2F92EE;'>#细胞代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77774, encryptionId=ba3be7774b6, topicName=细胞代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=771d11946860, createdName=yangshch, createdTime=Thu Dec 28 10:03:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631788, encodeId=ef441631e88ee, content=<a href='/topic/show?id=875e2542699' target=_blank style='color:#2F92EE;'>#代谢异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25426, encryptionId=875e2542699, topicName=代谢异常)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c06e21824720, createdName=bettycmoon, createdTime=Thu Dec 28 10:03:00 CST 2017, time=2017-12-28, status=1, ipAttribution=)]
    2018-06-13 yaanren
  3. [GetPortalCommentsPageByObjectIdResponse(id=2036164, encodeId=d25720361647f, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Fri May 25 09:03:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793987, encodeId=5aa11e9398759, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Jun 13 20:03:00 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724967, encodeId=0b381e2496788, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Fri Jul 20 22:03:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273402, encodeId=fe622e3402c4, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Dec 29 06:36:22 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252432, encodeId=67491252432c8, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Dec 28 10:03:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529464, encodeId=1a6715294645b, content=<a href='/topic/show?id=ba3be7774b6' target=_blank style='color:#2F92EE;'>#细胞代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77774, encryptionId=ba3be7774b6, topicName=细胞代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=771d11946860, createdName=yangshch, createdTime=Thu Dec 28 10:03:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631788, encodeId=ef441631e88ee, content=<a href='/topic/show?id=875e2542699' target=_blank style='color:#2F92EE;'>#代谢异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25426, encryptionId=875e2542699, topicName=代谢异常)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c06e21824720, createdName=bettycmoon, createdTime=Thu Dec 28 10:03:00 CST 2017, time=2017-12-28, status=1, ipAttribution=)]
    2018-07-20 zxxiang
  4. [GetPortalCommentsPageByObjectIdResponse(id=2036164, encodeId=d25720361647f, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Fri May 25 09:03:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793987, encodeId=5aa11e9398759, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Jun 13 20:03:00 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724967, encodeId=0b381e2496788, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Fri Jul 20 22:03:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273402, encodeId=fe622e3402c4, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Dec 29 06:36:22 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252432, encodeId=67491252432c8, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Dec 28 10:03:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529464, encodeId=1a6715294645b, content=<a href='/topic/show?id=ba3be7774b6' target=_blank style='color:#2F92EE;'>#细胞代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77774, encryptionId=ba3be7774b6, topicName=细胞代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=771d11946860, createdName=yangshch, createdTime=Thu Dec 28 10:03:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631788, encodeId=ef441631e88ee, content=<a href='/topic/show?id=875e2542699' target=_blank style='color:#2F92EE;'>#代谢异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25426, encryptionId=875e2542699, topicName=代谢异常)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c06e21824720, createdName=bettycmoon, createdTime=Thu Dec 28 10:03:00 CST 2017, time=2017-12-28, status=1, ipAttribution=)]
    2017-12-29 1e145228m78(暂无匿称)

    学习了谢谢作者分享!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2036164, encodeId=d25720361647f, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Fri May 25 09:03:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793987, encodeId=5aa11e9398759, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Jun 13 20:03:00 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724967, encodeId=0b381e2496788, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Fri Jul 20 22:03:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273402, encodeId=fe622e3402c4, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Dec 29 06:36:22 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252432, encodeId=67491252432c8, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Dec 28 10:03:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529464, encodeId=1a6715294645b, content=<a href='/topic/show?id=ba3be7774b6' target=_blank style='color:#2F92EE;'>#细胞代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77774, encryptionId=ba3be7774b6, topicName=细胞代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=771d11946860, createdName=yangshch, createdTime=Thu Dec 28 10:03:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631788, encodeId=ef441631e88ee, content=<a href='/topic/show?id=875e2542699' target=_blank style='color:#2F92EE;'>#代谢异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25426, encryptionId=875e2542699, topicName=代谢异常)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c06e21824720, createdName=bettycmoon, createdTime=Thu Dec 28 10:03:00 CST 2017, time=2017-12-28, status=1, ipAttribution=)]
    2017-12-28 yxch36
  6. [GetPortalCommentsPageByObjectIdResponse(id=2036164, encodeId=d25720361647f, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Fri May 25 09:03:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793987, encodeId=5aa11e9398759, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Jun 13 20:03:00 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724967, encodeId=0b381e2496788, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Fri Jul 20 22:03:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273402, encodeId=fe622e3402c4, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Dec 29 06:36:22 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252432, encodeId=67491252432c8, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Dec 28 10:03:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529464, encodeId=1a6715294645b, content=<a href='/topic/show?id=ba3be7774b6' target=_blank style='color:#2F92EE;'>#细胞代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77774, encryptionId=ba3be7774b6, topicName=细胞代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=771d11946860, createdName=yangshch, createdTime=Thu Dec 28 10:03:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631788, encodeId=ef441631e88ee, content=<a href='/topic/show?id=875e2542699' target=_blank style='color:#2F92EE;'>#代谢异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25426, encryptionId=875e2542699, topicName=代谢异常)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c06e21824720, createdName=bettycmoon, createdTime=Thu Dec 28 10:03:00 CST 2017, time=2017-12-28, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2036164, encodeId=d25720361647f, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Fri May 25 09:03:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793987, encodeId=5aa11e9398759, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Jun 13 20:03:00 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724967, encodeId=0b381e2496788, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Fri Jul 20 22:03:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273402, encodeId=fe622e3402c4, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Dec 29 06:36:22 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252432, encodeId=67491252432c8, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Dec 28 10:03:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529464, encodeId=1a6715294645b, content=<a href='/topic/show?id=ba3be7774b6' target=_blank style='color:#2F92EE;'>#细胞代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77774, encryptionId=ba3be7774b6, topicName=细胞代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=771d11946860, createdName=yangshch, createdTime=Thu Dec 28 10:03:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631788, encodeId=ef441631e88ee, content=<a href='/topic/show?id=875e2542699' target=_blank style='color:#2F92EE;'>#代谢异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25426, encryptionId=875e2542699, topicName=代谢异常)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c06e21824720, createdName=bettycmoon, createdTime=Thu Dec 28 10:03:00 CST 2017, time=2017-12-28, status=1, ipAttribution=)]

相关资讯

Diabetologia:为什么长期规律运动可降低民众患糖尿病风险?

明尼苏达州大学的Lisa S Chow博士和同事们发现,更高水平的心肺适能可显著降低成人患前驱糖尿病和糖尿病的风险,他们指出,通过规律体育锻炼可降低民众患前驱糖尿病和糖尿病的风险。研究发表在Diabetologia。Chow博士表示,许多既往研究显示通过运动维持或增加心肺适能的成年人相比不运动的成年人而言患糖尿病、代谢异常疾病、心血管疾病和心血管疾病死亡的风险更低。然而,这些既往研究得出的结论十分

JCO:靶向Met的单抗药物onartuzumab有望用于非小细胞肺癌治疗

  近期发表于临床肿瘤学杂志的一项2期临床试验结果显示:一种可阻断MET激活的新药onartuzumab对非小细胞肺癌(NSCLC)疗效显著。onartuzumab与 erlotinib联合治疗可使MET阳性(经免疫组化技术检测)的NSCLC患者获益,文章发表在10月份的JCO上。   基于上述结果,onartuzumab现已顺利进入3期临床试验阶段,在该阶段主要研究单药(厄洛替尼+

J Alzheimers Dis:瑜伽可降低痴呆症的发生风险

J Alzheimers Dis:瑜伽可降低痴呆症的发生风险目前还未有研究探究瑜伽对认知功能减退和静息状态功能连接的影响。本研究探究了轻度认知障碍患者(MCI)在瑜伽干预前后机体的记忆测试和静息态功能连接的性能,并与主动控制作对比。研究共纳入了25名(年龄≥55岁)MCI患者,随机分配分别接受瑜伽干预或主动控制(即增强记忆训练,MET),训练12周。使用静息态功能磁共振成像是用来评估大脑网络和记忆

ASCO 2013:二线治疗之Tivantinib的3期临床试验

Tivantinib是HGF的受体MET的抑制剂。这是一个3期临床试验,目标患者是在前期的全身治疗(包括索拉非尼)过程中进展或无法耐受的者,且肿瘤组织免疫组化染色证实MET高表达者。计划募集303名患者,按照2:1的比例随机接受tivantinib或安慰剂治疗。预期2015年中期可以完成研究。 Metiv-HCC: A phase III clinical trial evaluating ti

Cancer:MET表达可能是胃癌预后不良的预测靶点

一项来自我国中山大学肿瘤防治中心的研究结果表明:MET基因扩增和蛋白过度表达在胃癌的复发或转移的患者中并不少见,二者均与生存期大幅降低相关。这项回顾性研究的结果近期在线发表于Cancer杂志HGF/MET通路的异常激活会抑制细胞凋亡,促进癌细胞增殖、血管形成和转移。据研究者所提供的背景资料显示,在胃癌患者中,MET基因扩增是HGF/MET通路的异常激活的主要原因。该研究纳入了共232位在2005年